Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality.

Aged Aged, 80 and over COVID-19 / blood Female Hospital Mortality Humans Lupus Coagulation Inhibitor / blood Male Middle Aged Prognosis Prospective Studies Risk Factors Survival Rate Venous Thromboembolism / blood

Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
11 2021
Historique:
received: 16 12 2020
accepted: 16 04 2021
pubmed: 22 4 2021
medline: 17 11 2021
entrez: 21 4 2021
Statut: ppublish

Résumé

The clinical relevance of antiphospholipid antibodies (aPLs) in COVID-19 is controversial. This study was undertaken to investigate the prevalence and prognostic value of conventional and nonconventional aPLs in patients with COVID-19. This was a multicenter, prospective observational study in a French cohort of patients hospitalized with suspected COVID-19. Two hundred forty-nine patients were hospitalized with suspected COVID-19, in whom COVID-19 was confirmed in 154 and not confirmed in 95. We found a significant increase in lupus anticoagulant (LAC) positivity among patients with COVID-19 compared to patients without COVID-19 (60.9% versus 23.7%; P < 0.001), while prevalence of conventional aPLs (IgG and IgM anti-β Patients with COVID-19 have an increased prevalence of LAC positivity associated with biologic markers of inflammation. However, LAC positivity at the time of hospital admission is not associated with VTE risk and/or in-hospital mortality.

Identifiants

DOI: 10.1002/art.41777 PMID: 33881229 PMC: PMC8250965
pubmed: 33881229
doi: 10.1002/art.41777
pmc: PMC8250965
doi:

Substances chimiques

Lupus Coagulation Inhibitor 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1976-1985

Subventions

Organisme : Assistance Publique - Hôpitaux de Paris
Organisme : Agence Nationale de la Recherche

Informations de copyright

© 2021, American College of Rheumatology.

Références

Ann Intensive Care. 2020 Jul 16;10(1):95
pubmed: 32676824
J Thromb Haemost. 2009 Oct;7(10):1737-40
pubmed: 19624461
Front Immunol. 2018 Dec 14;9:2971
pubmed: 30619328
J Thromb Haemost. 2020 Nov;18(11):2828-2839
pubmed: 33462974
Arthritis Rheumatol. 2020 Nov;72(11):1953-1955
pubmed: 32564467
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
Thromb Haemost. 1996 Jul;76(1):65-8
pubmed: 8819253
Br J Haematol. 2001 Jun;113(3):621-9
pubmed: 11380447
Nat Rev Dis Primers. 2018 Jan 11;4:17103
pubmed: 29321641
JAMA Neurol. 2020 Jul 02;:
pubmed: 32614385
J Am Heart Assoc. 2020 Nov 3;9(21):e017773
pubmed: 32972320
Thromb Res. 2020 Nov;195:74-76
pubmed: 32663703
Front Immunol. 2020 Oct 15;11:584241
pubmed: 33178218
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
J Thromb Haemost. 2020 Sep;18(9):2191-2201
pubmed: 32619328
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
J Thromb Haemost. 2020 Sep;18(9):2391-2399
pubmed: 32558198
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Thromb Res. 2021 Jan;197:94-99
pubmed: 33190025
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
J Thromb Haemost. 2020 Aug;18(8):1846-1848
pubmed: 32428999
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Lupus. 2018 Apr;27(4):572-583
pubmed: 28945149
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111
Sci Transl Med. 2020 Nov 18;12(570):
pubmed: 33139519
J Thromb Haemost. 2013 Aug;11(8):1527-31
pubmed: 23601766
J Thromb Haemost. 2018 Apr;16(4):809-813
pubmed: 29532986
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
J Thromb Haemost. 2020 Aug;18(8):2064-2065
pubmed: 32324958
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32295896

Auteurs

Nicolas Gendron (N)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris. Centre-Université de Paris (APHP-CUP), F-75015, Paris, France.
ORCID: 0000-0003-4852-4738

Marie-Agnès Dragon-Durey (MA)

Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris, Team Inflammation, Complement and Cancer, F-75006, and Immunology Department, Georges Pompidou European Hospital, APHP-CUP, F-75015, Paris, France.

Richard Chocron (R)

Université de Paris, PARCC, INSERM, F-75015, and Emergency Department, APHP-CUP, F-75015, Paris, France.

Luc Darnige (L)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris. Centre-Université de Paris (APHP-CUP), F-75015, Paris, France.

Georges Jourdi (G)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department, APHP-CUP, F-75014, Paris, France.

Aurélien Philippe (A)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris. Centre-Université de Paris (APHP-CUP), F-75015, Paris, France.

Camille Chenevier-Gobeaux (C)

Department of Automated Diagnostic Biology, Hôpital Cochin, APHP-CUP, F-75014, Paris, France.

Jérôme Hadjadj (J)

Université de Paris Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, F-75015, and Paris Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, APHP-CUP, F-75014, Paris, France.

Jérôme Duchemin (J)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department, APHP-CUP, F-75014, Paris, France.

Lina Khider (L)

Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015, Paris, France.

Nader Yatim (N)

Translational Immunology Lab, Department of Immunology, Institut Pasteur, and Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, APHP-CUP, F-75015, Paris, France.

Guillaume Goudot (G)

Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015, Paris, France.

Daphné Krzisch (D)

Université de Paris, Hematology Department, APHP-CUP, F-75015, Paris, France.

Benjamin Debuc (B)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Plastic Surgery Department, APHP-CUP, F-75015, Paris, France.

Laetitia Mauge (L)

Université de Paris, PARCC, INSERM, F-75015, and Hematology Department, APHP-CUP, F-75015, Paris, France.

Françoise Levavasseur (F)

Université de Paris, Institut Cochin, INSERM, F-75014, Paris, France.

Frédéric Pene (F)

Intensive Care Medicine, APHP-CUP, F-75014, Paris, France.

Jeremy Boussier (J)

Translational Immunology Lab, Department of Immunology, Institut Pasteur, and Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, APHP-CUP, F-75015, Paris, France.

Elise Sourdeau (E)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department, APHP-CUP, F-75014, Paris, France.

Julie Brichet (J)

Université de Paris, Hematology Department, APHP-CUP, F-75015, Paris, France.

Nadège Ochat (N)

Université de Paris, Hematology Department, APHP-CUP, F-75015, Paris, France.

Claire Goulvestre (C)

Immunology Department, APHP-CUP, F-75014, Paris, France.

Christophe Peronino (C)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris. Centre-Université de Paris (APHP-CUP), F-75015, Paris, France.

Tali-Anne Szwebel (TA)

Translational Immunology Lab, Department of Immunology, Institut Pasteur, and Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, APHP-CUP, F-75015, Paris, France.

Franck Pages (F)

Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris, Team Inflammation, Complement and Cancer, F-75006, and Immunology Department, Georges Pompidou European Hospital, APHP-CUP, F-75015, Paris, France.

Pascale Gaussem (P)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department, APHP-CUP, F-75014, Paris, France.

Charles-Marc Samama (CM)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Anaesthesia, Intensive Care and Perioperative Medicine Department, APHP-CUP, F-75014, Paris, France.

Cherifa Cheurfa (C)

Anaesthesia, Intensive Care and Perioperative Medicine Department, APHP-CUP, F-75014, Paris, France.

Benjamin Planquette (B)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015 Paris, France and F-CRIN INNOVTE, Saint-Étienne, France.

Olivier Sanchez (O)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015 Paris, France and F-CRIN INNOVTE, Saint-Étienne, France.

Jean-Luc Diehl (JL)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015, Paris, France.

Tristan Mirault (T)

Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015, Paris, France.

Michaela Fontenay (M)

Université de Paris, Institut Cochin, INSERM, and Hematology Department, APHP-CUP, F-75014, Paris, France.

Benjamin Terrier (B)

Université de Paris, PARCC, INSERM U970, F-75015, and Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, APHP-CUP, F-75014, Paris, France.
ORCID: 0000-0001-6612-7336

David M Smadja (DM)

Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, and Hematology Department and Biosurgical Research Lab (Carpentier Foundation), APHP-CUP, F-75015 Paris, France and F-CRIN INNOVTE, Saint-Étienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Mortalité hospitalière › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Facteurs biologiques › Inhibiteurs des facteurs de la coagulation sanguine › Inhibiteur lupique de la coagulation › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Diagnostic › Pronostic › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Lupus Anticoagulant Single Positivity During...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Embolie et thrombose › Thromboembolie › Thromboembolisme veineux › Lupus Anticoagulant Single Positivity During...